TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8188164
Drug: Optimal conditions
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal conditions for serum specimen preparation (immediate centrifugation after clot formation)
Study: 12629094
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 4 IU/m².d (approximately 0.045 mg/kg/d)
Study: 12629094
Drug: After starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: After starting estrogen treatment
Study: 27543470
Drug: Early direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early direct current cardioversion (DCCV) and oral Amiodarone for 6 weeks (Group 2)
Study: 22868212
Drug: 0.2 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/kg NMC
Study: 22868212
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg NMC
Study: 22868212
Drug: 12.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 μg/kg NMC
Study: 22868212
Drug: 50.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.0 μg/kg NMC
Study: 22868212
Drug: 2.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg/kg GRP
Study: 22868212
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg NMC + 20.0 μg/kg [d‐Lys(3)]‐GHRP‐6
Study: 22868212
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg NMC + 20.0 μg/kg N‐GRP‐EE
Study: 22868212
Drug: 20.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.0 μg/kg N‐GRP‐EE
Study: 22868212
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg NMB
Study: 22868212
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg NMC in pre-weaned calves
Study: 22868212
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg NMC in rats
Study: 21126666
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of warm fluids at 37° C
Study: 21126666
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of room temperature fluids
Study: 19079957
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oral cabergoline per day for 3 weeks beginning on the day after oocyte retrieval
Study: 15690266
Drug: Spinal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal 2-chloroprocaine 10 mg
Study: 15690266
Drug: Spinal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal 2-chloroprocaine 20 mg
Study: 15690266
Drug: Spinal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal 2-chloroprocaine 30 mg
Study: 15690266
Drug: Spinal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal 2-chloroprocaine 40 mg
Study: 15690266
Drug: Spinal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal 2-chloroprocaine 60 mg
Study: 15690266
Drug: Spinal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal 2-chloroprocaine 10 mg to 60 mg
Study: 7573470
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of H2SO4 aerosol (1,000 microgram/m3)
Study: 7573470
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of NaCl aerosol (control)
Study: 19636555
Drug: Oral leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leucovorin (LV) at a single dose of 25 mg administered 4 hours before surgery
Study: 19636555
Drug: Oral leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leucovorin (LV) at a single dose of 25 mg administered 12 hours before surgery
Study: 19636555
Drug: Oral leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leucovorin (LV) at a single dose of 25 mg administered 18 hours before surgery
Study: 19636555
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LV administration)
Study: 15265397
Drug: Submucosal injection
Normalized name: Mepivacaine Hydrochloride 30 mg in 1 mL SUBMUCOSAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal injection of pirarubicin
Study: 3158675
Drug: Zimelidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine 200 mg/24 hours for 10 days
Study: 3158675
Drug: Ethanol 0.5
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.5 and 1.0 g/kg of body weight
Study: 29747432
Drug: Mangosteen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mangosteen extract with behavioral therapy
Study: 12814445
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose insulin (6 pmol min-1) + C-peptide (2-60 pmol min-1)
Study: 12814445
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose insulin (30 pmol min-1) + C-peptide
Study: 12814445
Drug: C-peptide (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide (during low dose insulin)
Study: 2568765
Drug: Lofexidine (L)
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lofexidine (L)
Study: 20889523
Drug: High-dose vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamins C and E (1000 mg vitamin C and 400 IU RRR α-tocopherol daily)
Study: 11918761
Drug: Bicarbonate-buffered PD
Normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate-buffered PD solution (34 mmol/L, pH 7.4)
Study: 11918761
Drug: Lactate-buffered PD
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal PD-2/2.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate-buffered PD solution (35 mmol/L, pH 5.5)
Study: 11918761
Drug: Both bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both bicarbonate and lactate buffered PD solutions
Study: 7762389
Drug: Oxymetazoline nasal
Normalized name: oxymetazoline nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline nasal spray once daily at night
Study: 7762389
Drug: Oxymetazoline nasal
Normalized name: oxymetazoline nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline nasal spray three times daily
Study: 2221729
Drug: Trimetazidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (3 tablets daily for one month)
Study: 342043
Drug: Topical ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ampicillin (1 g applied to the wound)
Study: 6196515
Drug: High-dose neuraminidase-treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose neuraminidase-treated allogeneic blasts
Study: 6196515
Drug: Specific monoclonal
Normalized name: Bispecific monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific monoclonal antibodies or autologous cytotoxic T-cells
Study: 26802011
Drug: Patient-centered, tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centered, tablet computer-based self-monitoring system
Study: 25503160
Drug: Polaprezinc in
Normalized name: polaprezinc
DrugBank: Polaprezinc (DB09221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc in sodium alginate suspension (P‐AG)
Study: 20854207
Drug: Dapivirine gel
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine gel (0.001%, 0.005%, or 0.02%) once daily on Days 1 and 10 and twice daily on Days 2-9
Study: 20854207
Drug: Dapivirine gel
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine gel (0.001%, 0.005%, or 0.02%)
Study: 11950252
Drug: Valdecoxib 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 5 mg
Study: 12209034
Drug: Valdecoxib 10
Normalized name: valdecoxib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 10 mg
Study: 12100776
Drug: Valdecoxib 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 5 mg and 10 mg
Study: 2803090
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg/d)
Study: 26014292
Drug: Dexrazoxane (10:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexrazoxane (10:1 ratio with doxorubicin, cumulative dose of 100 to 360 mg/m2)
Study: 23862400
Drug: Intranasal sodium
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sodium hyaluronate 9 mg twice daily for 30 days
Study: 18579227
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol)
Study: 10716083
Drug: Moxifloxacin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (1 x 400 mg tablet in the morning and 1 placebo tablet in the evening for 7 days)
Study: 10716083
Drug: Clarithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (1 x 500 mg tablet in the morning and 1 x 500 mg tablet in the evening for 7 days)
Study: 31301609
Drug: Daily patient-reported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily patient-reported anxiety measured using smartphones
Study: 28840585
Drug: Quxie Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quxie Capsule combined with conventional therapy
Study: 28840585
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with conventional therapy
Study: 8844447
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 1005 (250 mg twice daily)
Study: 8844447
Drug: theophylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: theophylline (400 mg twice daily)
Study: 8844447
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 1005 and theophylline concomitantly (treatment C)
Study: 1621751
Drug: Loracarbef (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef (200 mg, twice daily)
Study: 1621751
Drug: Cefaclor (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (250 mg, three times daily)
Study: 6463091
Drug: d-amphetamine (5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (5-30 mg)
Study: 28741741
Drug: Pregabalin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin after low dose of morphine
Study: 26803590
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 and folic acid/B12 treatment
Study: 26803590
Drug: Folic acid/B12
Normalized name: iron/folic acid/B12/C/docusate 90 mg-1 mg-12 mcg-120 mg-50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid/B12 treatment
Study: 18753861
Drug: Entecavir 1
Normalized name: entecavir 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1 mg once daily for 24 weeks
Study: 12540412
Drug: Acipimox (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (500 mg at -90 and 0 min)
Study: 8510517
Drug: Recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant growth hormone (rGH) therapy for 12 months
Study: 27223641
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg orally, twice daily preoperatively, and 0.5 mg, twice daily until hospital discharge)
Study: 24329187
Drug: Risperidone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 2.5 mg
Study: 10461448
Drug: Ceftibuten 400
Normalized name: ceftibuten 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 400 mg or 9 mg/kgbw/day (Group B)
Study: 10461448
Drug: Parenteral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral therapy (Group A)
Study: 8150836
Drug: Collagenase ointment
Normalized name: collagenase Topical Ointment
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collagenase ointment and polymyxin B sulfate/bacitracin spray
Study: 4343464
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation with diazepam alone
Study: 4343464
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation with diazepam and atropine
Study: 4343464
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation with chlormethiazole
Study: 28627290
Drug: Continuous adductor
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous adductor canal block (ACB) with 0.2% ropivacaine, 20 mL bolus followed by continuous flow at 6 mL/h for 2 days
Study: 28627290
Drug: Single-dose local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose local infiltration anesthesia (LIA) alone
Study: 24350813
Drug: Risperidone (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (maximum weight-based dose of 1.25 mg/day for 20 to <45 kg, and 1.75 mg/day for ≥ 45 kg)
Study: 26676082
Drug: Augmentation procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation procedure
Study: 24911814
Drug: Pain Group
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Group (topical capsaicin cream)
Study: 23213981
Drug: Medication (salvia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (salvia injectio and mecobalamin)
Study: 16415626
Drug: Infant massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant massage (tactile and kinesthetic stimulation), administered twice daily for 10 days.
Study: 12444335
Drug: 0.12% betamethasone‐17‐valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% betamethasone‐17‐valerate ointment
Study: 17429636
Drug: LEF (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEF (100 mg/day for 3 days followed by 20 mg/day)
Study: 17429636
Drug: MTX (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (25 mg once weekly)
Study: 8489567
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release formulation (300 mg, applied twice a day)
Study: 8489567
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulation (400 mg, applied once a day in the evening)
Study: 8489567
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release formulation (300 mg)
Study: 8489567
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulation (400 mg)
Study: 3583456
Drug: Oral nourishment
Normalized name: Lantiseptic Nourishing Skin
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nourishment
Study: 3583456
Drug: Intravenous nourishment
Normalized name: Lantiseptic Nourishing Skin
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nourishment
Study: 3583456
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous nourishment
Study: 29957714
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (twice daily sessions of manual mobilization and 30‐minute passive/active cycling therapy)
Study: 27248838
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (aPDT)
Study: 27248838
Drug: Tongue scraper
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue scraper and photodynamic therapy
Study: 23002547
Drug: Kurarinol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kurarinol (single drug group)
Study: 19501011
Drug: Comprehension questionnaire
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehension questionnaire administered at the end of the clinical trial
Study: 18396361
Drug: Na-ASP-2 vaccine
Normalized name: sodium lauroyl aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na-ASP-2 vaccine (10 microg)
Study: 18396361
Drug: Na-ASP-2 vaccine
Normalized name: sodium lauroyl aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na-ASP-2 vaccine (50 microg)
Study: 18396361
Drug: Na-ASP-2 vaccine
Normalized name: sodium lauroyl aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na-ASP-2 vaccine (100 microg)
Study: 15647416
Drug: Anidulafungin 200
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anidulafungin 200 mg intravenous loading dose followed by 100 mg intravenous maintenance dose (days 2-8)
Study: 15647416
Drug: Cyclosporine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 1.25 mg/kg oral solution twice daily (days 5-8)
Study: 10470636
Drug: Spinal Anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Anesthesia (10 mg of hyperbaric tetracaine intrathecally)
Study: 10470636
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Anesthesia (fentanyl i.v. 1 to 2 micrograms/kg, propofol i.v. 1.0 to 2.0 mg/kg, isoflurane end-tidal 0.7% to 1.2%, 70% nitrous oxide in oxygen)
Study: 28364511
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) and Active Behavioral Desensitization Control (BD)
Study: 17251875
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (50 mg/kg bolus followed by 8.3 mg/kg/hr infusion for 24 hr)
Study: 15835374
Drug: Micardis (Telmisartan)
Normalized name: telmisartan Oral Tablet [Micardis]
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micardis (Telmisartan) with low-dose aspirin
Study: 12207634
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg methotrexate (MTX)
Study: 12207634
Drug: AUC(24,36 h)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUC(24,36 h) >= 700 nmol l(‐1) h
Study: 12207634
Drug: AUC(24,36 h)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUC(24,36 h) < 700 nmol l(‐1) h
Study: 8951627
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg 1 x daily for 3 days
Study: 1758817
Drug: MS Contin
Normalized name: MS Contin
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS Contin tablet 200 mg (controlled release morphine sulphate)
Study: 27199859
Drug: Animal Assisted
Normalized name: animals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal Assisted Therapy (AAT) treatment group (n = 14) participated in twice-weekly 1-hour sessions of AAT
Study: 21353111
Drug: Ibuprofen alone
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen alone (10 mg/kg)
Study: 21353111
Drug: Ibuprofen combined
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen combined with acetaminophen (10 mg/kg ibuprofen + 15 mg/kg acetaminophen)
Study: 21353111
Drug: Ibuprofen followed
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen followed by acetaminophen (10 mg/kg ibuprofen followed by 15 mg/kg acetaminophen 3 hours later)
Study: 16754526
Drug: Limited intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited intervention (one visit with asthma self‐management education and provision of inhaled budesonide)
Study: 9289706
Drug: Obese patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obese patients with disturbances in carbohydrate and lipid metabolism
Study: 9289706
Drug: Obese patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obese patients with disturbance in lipid metabolism
Study: 1475671
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene motivation tool (Parograph)
Study: 6228196
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin (13‐cis‐retinoic acid) for four months
Study: 27302514
Drug: Photon radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Photon radiation therapy (XRT)
Study: 19653744
Drug: Presentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation of letters pairs (e.g., A-Z)
Study: 19653744
Drug: Presentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation of mixed digit-letter pairs (e.g., 1-Z)
Study: 17326881
Drug: Dinoprostone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (0.5 mg PGE(2) gel intracervically every 6 h, max three doses in 24 h)
Study: 15871365
Drug: Itopride hydrochloride
Normalized name: Itopride hydrochloride
DrugBank: Itopride (DB04924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride hydrochloride (Ganaton) 50 mg three times daily for 2 weeks
Study: 15871365
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate 5 mg three times daily for 2 weeks
Study: 9531075
Drug: Thymostimulin, 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin, 70 mg i.m. qd for the first month and every other day thereafter
Study: 9531075
Drug: Short-term antimicrobial
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term antimicrobial chemoprophylaxis with pefloxacin (800 mg i.v. qd for the first 4 days) and polychemotherapy with teicoplanin (800 mg i.v. qd) and netilmicin (300 mg i.m. qd)
Study: 25511214
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg fentanyl added to 0.5% bupivacaine
Study: 25511214
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline mixed with 10 ml of 0.5% bupivacaine
Study: 18072125
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of droperidol (DROP) IM